Display options
Cite
Mozaffarian N, Lobosco S, Lu P, et al. Satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectives. Patient Prefer Adherence. 2016;10:2051-2061doi: 10.2147/PPA.S111725.
Mozaffarian, N., Lobosco, S., Lu, P., Roughley, A., & Alperovich, G. (2016). Satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectives. Patient preference and adherence, 102051-2061. https://doi.org/10.2147/PPA.S111725
Mozaffarian, Neelufar, et al. "Satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectives." Patient preference and adherence vol. 10 (2016): 2051-2061. doi: https://doi.org/10.2147/PPA.S111725
Mozaffarian N, Lobosco S, Lu P, Roughley A, Alperovich G. Satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectives. Patient Prefer Adherence. 2016 Oct 04;10:2051-2061. doi: 10.2147/PPA.S111725. eCollection 2016. PMID: 27784995; PMCID: PMC5063293.
Copy Download .nbib Format: NLM
Share it on

Patient Prefer Adherence. 2016 Oct 04;10:2051-2061. doi: 10.2147/PPA.S111725. eCollection 2016.

Satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectives.

Patient preference and adherence

Neelufar Mozaffarian, Steve Lobosco, Peng Lu, Adam Roughley, Gabriela Alperovich

Affiliations

  1. Clinical Development, AbbVie Inc., North Chicago, USA.
  2. Adelphi Real World Ltd., Macclesfield, UK.
  3. Clinical Development, AbbVie Inc., Worcester, MA, USA.
  4. Global Medical Affairs Immunology, AbbVie Inc., Madrid, Spain.

PMID: 27784995 PMCID: PMC5063293 DOI: 10.2147/PPA.S111725

Abstract

PURPOSE: Patient satisfaction with disease control of systemic lupus erythematosus (SLE) is an important component of medical management. This analysis evaluated patient and physician satisfaction with disease control of SLE, factors associated with satisfaction/dissatisfaction, and the degree of physician-patient concordance of these parameters.

PATIENTS AND METHODS: Data were extracted from the US Adelphi Real World Lupus Disease Specific Programme

RESULTS: Physicians reported moderate or severe disease activity in 25.0% of patients with NNSLE and in 50.5% of patients with LN, and were satisfied with disease control in 78.6% (132/168) and 73.8% (152/206) of patients, respectively. For patients, 75.8% (75/99) with NNSLE were satisfied with their current treatment, compared with 65.5% (74/113) with LN. Physician-patient agreement (70.7%) on the level of satisfaction was "slight" (kappa =0.1445) for NNSLE; patients were more frequently dissatisfied than physicians with regard to joint tenderness, fatigue, anxiety, pain on movement, malar rash, and photosensitivity. Physician-patient agreement (71.4%) on the level of satisfaction was "fair" (kappa =0.3695) for LN; patients expressed greater dissatisfaction than physicians for headache, photosensitivity, and anxiety, whereas physicians were more dissatisfied with regard to joint swelling, kidney function, and blood pressure control. In general, patients with NNSLE or LN who were dissatisfied (or whose physicians were dissatisfied) were more likely to have joint swelling, joint stiffness, malar rash, hair loss, depression, and fatigue, have moderate or severe disease, or to be currently experiencing disease flare.

CONCLUSION: These data highlight the patient and physician dissatisfaction with real-world disease control of SLE.

Keywords: agreement; concordance; disease control; lupus; satisfaction

Conflict of interest statement

SL and AR are employed by Adelphi Real World Ltd. GA is an AbbVie employee. NM was employed by AbbVie at the time of the research and is currently employed by Gilead Sciences, Inc. PL was employed by

References

  1. J Rheumatol. 2000 Mar;27(3):675-9 - PubMed
  2. Lupus. 2006;15(5):308-18 - PubMed
  3. Lupus. 2010 Jan;19(1):100-6 - PubMed
  4. Scand J Rheumatol. 2009 Mar-Apr;38(2):121-7 - PubMed
  5. J Pain Symptom Manage. 1997 Feb;13(2):63-74 - PubMed
  6. J Behav Med. 1994 Oct;17(5):459-77 - PubMed
  7. Ann Acad Med Singapore. 2007 Feb;36(2):115-22 - PubMed
  8. J Rheumatol. 2005 May;32(5):913-9 - PubMed
  9. Lupus. 2013 Sep;22(10):1038-45 - PubMed
  10. Ann Rheum Dis. 2012 Jun;71(6):918-23 - PubMed
  11. Ann Rheum Dis. 2014 Jun;73(6):958-67 - PubMed
  12. Depress Anxiety. 2009;26(6):575-82 - PubMed
  13. Rheumatol Int. 2016 May;36(5):725-9 - PubMed
  14. Arthritis Care Res (Hoboken). 2012 Aug;64(8):1261-4 - PubMed
  15. Biometrics. 1977 Mar;33(1):159-74 - PubMed
  16. J Rheumatol. 2003 Sep;30(9):1967-76 - PubMed
  17. Pol Arch Med Wewn. 2013;123(9):482-90 - PubMed
  18. Indian J Pathol Microbiol. 2000 Jul;43(3):311-7 - PubMed
  19. Lupus. 2013 Jul;22(8):819-26 - PubMed
  20. Am J Reprod Immunol. 2004 May;51(5):336-40 - PubMed
  21. Scand J Rheumatol. 2012 Oct;41(5):383-90 - PubMed
  22. J Rheumatol. 1999 Nov;26(11):2352-6 - PubMed

Publication Types